Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Costs and Expenses:
General and administrative	$ 1,393,000	$ 1,154,000
Research and development	1,635,000	2,418,000
Total Operating Costs and Expenses	3,028,000	3,572,000
Loss from Operations	(3,028,000)	(3,572,000)
Other Income :
Interest income	38,000	44,000
Total Other Income	38,000	44,000
Net Loss	(2,990,000)	(3,528,000)
Net Loss Attributable to Non-controlling Interest	(26,000)	(16,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(2,964,000)	(3,512,000)
Net Loss Attributable to Common Stockholders	$ (3,430,000)	$ (3,971,000)
Net Loss Per Share - Basic and Dilutive	$ (0.20)	$ (0.25)
Weighted average number of shares outstanding during the period - Basic and Dilutive	17,093,920	15,656,784
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (62,000)	$ (61,000)
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0
Preferred Stock Dividends, Income Statement Impact	$ (404,000)	$ (398,000)